Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy

Explore clinical trials studying Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study

Refine in advanced search Browse all conditions

Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy trial results

Recruiting

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

NCT06599697

Conditions: Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
Locations: University of Alabama at Birmingham Birmingham, Alabama, United States

Johns Hopkins University Baltimore, Maryland, United States

University of Pittsburgh Pittsburgh, Pennsylvania, United States

University of Texas Health Science Center at Houston Houston, Texas, United States

View Trial Details